Medicines Approved for Specific Cancers (M to Z)
Drugs Approved for Malignant Mesothelioma
Pemetrexed
Ipilimumab
Nivolumab
Drugs Approved for Melanoma
Aldesleukin
Binimetinib
Bravtovi
Cobimetinib
Dabrafenib
Dacarbazine
Encorafenib
Imlygic
Interferon
Ipilimumab
Nivolumab
Pembrolizumab
Talimogene Laherparepvec
Trametinib
Vemurafenib
Drugs Approved for Multicentric Castleman Disease
Siltuximab
Drugs Approved for Multiple Myeloma and Other Plasma Cell Neoplasms
Belantamab Mafodotin-blmf
Bortezomib
Carfilzomib
Carmustine
Cyclophosphamide
Daratumumab
Daratumumab and Hyaluronidase-fihj
Elotuzumab
Isatuximab-irfc
Ixazomib
Lenalidomide
Melphalan
Pamidronate
Panobinostat
Plerixafor
Pomalidomide
Selinexor
Thalidomide
Zoledronic Acid
Drugs Approved for Myeloproliferative Neoplasms
Arsenic Trioxide
Azacitidine
Cyclophosphamide
Cytarabine
Dasatinib
Daunorubicin
Decitabine
Doxorubicin
Fedratinib
Imatinib Mesylate
Nilotinib
Ruxolitinib
Drugs Approved for Neuroblastoma
Cyclophosphamide
Dinutuximab
Doxorubicin
Vincristine
Drugs Approved for Non-Hodgkin’s Lymphoma
Acalabrutinib
Belinostat
Bendamustine
Bleomycin
Bortezomib
Brentuximab Vedotin
Brexucabtagene Autoleucel
Carmustine
Chlorambucil
Copanlisib
Cyclophosphamide
Denileukin Diftitox
Dexamethasone
Doxorubicin
Duvelisib
Ibritumomab
Ibrutinib
Idelalisib
Interferon
Lenalidomide
Methotrexate
Mogamulizumab-kpkc
Nelarabine
Obinutuzumab
Pembrolizumab
Plerixafor
Polatuzumab Vedotin-piiq
Pralatrexate
Prednisone
Rituximab
Romidepsin
Selinexor
Tafasitamab-cxix
Tazemetostat Hydrobromide
Tisagenlecleucel
Venetoclax
Vinblastine
Vincristine
Vorinostat
Zanubrutinib
Drugs Approved for Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Bevacizumab
Carboplatin
Cisplatin
Cyclophosphamide
Doxorubicin
Gemcitabine
Melphalan
Niraparib
Olaparib
Paclitaxel
Rucaparib
Thiotepa
Topotecan
Drugs Approved for Pancreatic Cancer
Erlotinib
Everolimus
Fluorouracil
Gemcitabine
Irinotecan
Mitomycin
Olaparib
Paclitaxel
Sunitinib
Tarceva
Drugs Approved for Penile Cancer
Bleomycin
Drugs Approved for Prostate Cancer
Abiraterone
Apalutamide
Bicalutamide
Cabazitaxel
Darolutamide
Degarelix
Docetaxel
Enzalutamide
Flutamide
Goserelin
Leuprolide
Mitoxantrone
Nilutamide
Olaparib
Rucaparib
Sipuleucel-T
Drugs Approved for Retinoblastoma
Cyclophosphamide
Drugs Approved for Rhabdomyosarcoma
Dactinomycin
Vincristine
Drugs Approved for Melanoma
Aldesleukin
Cobimetinib
Dabrafenib
Dacarbazine
Interferon
Ipilimumab
Nivolumab
Pembrolizumab
Talimogene Laherparepvec
Trametinib
Vemurafenib
Drugs Approved for Merkel Cell Carcinoma
Avelumab
Pembrolizumab
Drugs Approved for Basal Cell Carcinoma
Fluorouracil
Imiquimod
Sonidegib
Vismodegib
Drugs Approved for Cutaneous Squamous Cell Carcinoma
Cemiplimab-rwlc
Pembrolizumab
Drugs Approved for Soft Tissue Sarcoma
Dactinomycin
Doxorubicin
Eribulin
Imatinib
Pazopanib
Tazemetostat
Trabectedin
Drugs Approved for Stomach Cancer
Docetaxel
Doxorubicin
Fluorouracil
Mitomycin
Pembrolizumab
Ramucirumab
Trastuzumab
Trifluridine and Tipiracil
Drugs Approved for Testicular Cancer
Bleomycin
Cisplatin
Dactinomycin
Etoposide
Ifosfamide
Vinblastine
Drugs Approved for Thyroid Cancer
Cabozantinib
Dabrafenib
Doxorubicin
Lenvatinib
Selpercatinib
Sorafenib
Trametinib
Vandetanib
Drugs Approved for Vulvar Cancer
Bleomycin
Drugs Approved for Wilms Tumor
Dactinomycin
Doxorubicin
Vincristine
Other Cancers
Medicines Approved for Specific Cancers (A-D)